Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Solara Active Pharma Sciences Ltd.
Source DateBoard Meeting DateDetails
07-May-2025 15-May-2025 Audited Results
26-Mar-2025 02-Apr-2025 Inter-alia, to consider and approve:- (1) the First Call money Notice, on the partly paid Equity Shares issued on Rights basis which is to be sent to the eligible Shareholders
20-Mar-2025 26-Mar-2025 Inter alia, to consider and approve :- a) To consider and approve, a proposal of making First Call on 1,19,98,755 partly paid-up Equity Shares, having a face value of Rs.10/- each (Rs.3.50/- paid-up) issued by the Company on rights basis in accordance with the Letter of Offer dated May 09, 2024. b) Any other matters, which may be incidental and ancillary to making aforesaid first call.
16-Jan-2025 24-Jan-2025 Quarterly Results
14-Oct-2024 21-Oct-2024 Quarterly Results
15-Jul-2024 22-Jul-2024 Quarterly Results
21-May-2024 29-May-2024 Audited Results
05-Feb-2024 14-Feb-2024 Quarterly Results
08-Nov-2023 14-Nov-2023 Quarterly Results
07-Aug-2023 14-Aug-2023 Quarterly Results (Revised)
04-Aug-2023 11-Aug-2023 Quarterly Results
30-Jun-2023 05-Jul-2023 Right Issue of Equity Shares
04-May-2023 12-May-2023 Audited Results
19-Jan-2023 25-Jan-2023 Quarterly Results
02-Nov-2022 09-Nov-2022 Quarterly Results
28-Jul-2022 04-Aug-2022 Quarterly Results
22-Apr-2022 29-Apr-2022 Dividend & Audited Results
31-Jan-2022 09-Feb-2022 Quarterly Results
03-Nov-2021 11-Nov-2021 Quarterly Results
27-Jul-2021 04-Aug-2021 Quarterly Results
Page 1 of 2
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.